Algeta believes in the potential of its alpha-pharmaceutical research program beyond radium-223, and is looking to expand its technology platform to target a broader range of cancers using thorium-227.
Algeta is evaluating the potential utility of alpha-particle emitting elements in the treatment of cancer. Thorium-227 is one alpha-particle emitting element (radionuclide) that has been selected by Algeta for further investigation. By linking thorium-227 to targeting molecules such as monoclonal antibodies, Algeta believes it may be possible to develop a pipeline of targeted alpha-pharmaceuticals, termed Targeted Thorium Conjugates (TTCs).
"Working to advance its TTC portfolio is the next step in Algeta’s efforts to expand and commercialize its technologies"
Being able to precisely deliver a payload of thorium-227 to a specific part of the body could enable Algeta to address a range of cancer indications.
In addition to collaborating on two programs with Sanofi and Ablynx, Algeta has licensed molecules from Affibody. Two further programs will target cancers of the blood, including a collaboration with Immunomedics.
In working to advance its TTC portfolio, Algeta seeks to address clear, unmet clinical needs in the oncology space, and potentially have a significant effect on patient outcomes.